**Core Concept:** Antiemetics are medications used to prevent and treat nausea and vomiting. Radiotherapy can cause emesis as one of its side effects due to its cytotoxic effects on the gastrointestinal tract and central nervous system.

**Why the Correct Answer is Right:** Doxorubicin is a chemotherapeutic agent that belongs to the group of drugs known as anthracyclines. It is frequently used in the treatment of various cancers, including breast, lung, and lymphoma cancers. However, it is known to cause emesis when administered, particularly in high doses.

**Why Each Wrong Option is Incorrect:**

A. Dexamethasone (Option A) is a corticosteroid that has anti-inflammatory and immunosuppressive effects. Although it can be used as an antiemetic in certain cases, it is not specifically designed to combat emesis caused by doxorubicin.

B. Ondansetron (Option B) is a selective serotonin receptor antagonist, primarily targeting the 5-HT3 receptors in the gastrointestinal tract. While it is an effective antiemetic, it is not the most suitable option for preventing emesis specifically caused by doxorubicin.

C. Granisetron (Option C) is a selective 5-HT3 receptor antagonist, similar to ondansetron. While it is also effective in preventing emesis, it is not the most specific choice for combating doxorubicin-induced emesis.

D. Palonosetron (Option D) is a second-generation 5-HT3 receptor antagonist. Like granisetron, it is effective in preventing emesis but is not specifically designed to counteract doxorubicin-induced emesis.

**Clinical Pearl:** For optimal management of doxorubicin-induced emesis, a combination of antiemetics targeting different pathways is recommended, such as using a 5-HT3 receptor antagonist (ondansetron, granisetron, palonosetron, or a combination of these) in combination with dexamethasone or aprepitant for neurotoxic emesis caused by doxorubicin.

**Correct Answer:** Doxorubicin-induced emesis is managed best by combining a 5-HT3 receptor antagonist (such as palonosetron) with dexamethasone. This combination provides comprehensive coverage of the different emetic pathways involved in chemotherapy-induced emesis, including the neurotoxic pathway activated by doxorubicin.